- Home
- DRRX vs RNXT Comparison
DRRX vs RNXT Comparison
Compare DRRX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- RNXT
- Stock Information
- Founded
- DRRX 1998
- RNXT 2012
- Country
- DRRX United States
- RNXT United States
- Employees
- DRRX N/A
- RNXT N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- RNXT Health Care
- Exchange
- DRRX Nasdaq
- RNXT Nasdaq
- Market Cap
- DRRX 26.3M
- RNXT 31.6M
- IPO Year
- DRRX 2000
- RNXT 2021
- Fundamental
- Price
- DRRX $0.80
- RNXT $1.03
- Analyst Decision
- DRRX Buy
- RNXT Strong Buy
- Analyst Count
- DRRX 2
- RNXT 1
- Target Price
- DRRX $5.00
- RNXT $9.00
- AVG Volume (30 Days)
- DRRX 54.3K
- RNXT 218.8K
- Earning Date
- DRRX 03-26-2025
- RNXT 03-31-2025
- Dividend Yield
- DRRX N/A
- RNXT N/A
- EPS Growth
- DRRX N/A
- RNXT N/A
- EPS
- DRRX N/A
- RNXT N/A
- Revenue
- DRRX $8,594,000.00
- RNXT N/A
- Revenue This Year
- DRRX $54.32
- RNXT N/A
- Revenue Next Year
- DRRX N/A
- RNXT N/A
- P/E Ratio
- DRRX N/A
- RNXT N/A
- Revenue Growth
- DRRX N/A
- RNXT N/A
- 52 Week Low
- DRRX $0.70
- RNXT $0.77
- 52 Week High
- DRRX $1.88
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- DRRX 49.63
- RNXT 35.37
- Support Level
- DRRX $0.73
- RNXT $1.00
- Resistance Level
- DRRX $0.83
- RNXT $1.18
- Average True Range (ATR)
- DRRX 0.05
- RNXT 0.10
- MACD
- DRRX 0.01
- RNXT -0.03
- Stochastic Oscillator
- DRRX 63.57
- RNXT 6.00
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.